1s9q › Citations

Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.

Greschik H, Flaig R, Renaud JP, Moras D
J Biol Chem 279 33639-46 (2004)
Related entries: 1s9p, 1tfc, 1vjb

Cited: 66 times
EuropePMC logo PMID: 15161930

Abstract

The estrogen-related receptor (ERR) gamma behaves as a constitutive activator of transcription. Although no natural ligand is known, ERRgamma is deactivated by the estrogen receptor (ER) agonist diethylstilbestrol and the selective ER modulator 4-hydroxytamoxifen but does not significantly respond to estradiol or raloxifene. Here we report the crystal structures of the ERRgamma ligand binding domain (LBD) complexed with diethylstilbestrol or 4-hydroxytamoxifen. Antagonist binding to ERRgamma results in a rotation of the side chain of Phe-435 that partially fills the cavity of the apoLBD. The new rotamer of Phe-435 displaces the "activation helix" (helix 12) from the agonist position observed in the absence of ligand. In contrast to the complexes of the ERalpha LBD with 4-hydroxytamoxifen or raloxifene, helix 12 of antagonist-bound ERRgamma does not occupy the coactivator groove but appears to be completely dissociated from the LBD body. Comparison of the ligand-bound LBDs of ERRgamma and ERalpha reveals small but significant differences in the architecture of the ligand binding pockets that result in a slightly shifted binding position of diethylstilbestrol and a small rotation of 4-hydroxytamoxifen in the cavity of ERRgamma relative to ERalpha. Our results provide detailed molecular insight into the conformational changes occurring upon binding of synthetic antagonists to the constitutive orphan receptor ERRgamma and reveal structural differences with ERs that explain why ERRgamma does not bind estradiol or raloxifene and will help to design new selective antagonists.

Articles - 1s9q mentioned but not cited (1)

  1. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. Bottegoni G, Kufareva I, Totrov M, Abagyan R. J Med Chem 52 397-406 (2009)


Reviews citing this publication (21)

  1. Overview of nomenclature of nuclear receptors. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Pharmacol Rev 58 685-704 (2006)
  2. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Ascenzi P, Bocedi A, Marino M. Mol Aspects Med 27 299-402 (2006)
  3. Ligand control of coregulator recruitment to nuclear receptors. Nettles KW, Greene GL. Annu Rev Physiol 67 309-333 (2005)
  4. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Deblois G, Giguère V. Nat Rev Cancer 13 27-36 (2013)
  5. Nuclear receptors, mitochondria and lipid metabolism. Alaynick WA. Mitochondrion 8 329-337 (2008)
  6. Looking at nuclear receptors from a new angle. Helsen C, Claessens F. Mol Cell Endocrinol 382 97-106 (2014)
  7. The NR3B subgroup: an ovERRview. Tremblay AM, Giguère V. Nucl Recept Signal 5 e009 (2007)
  8. Stabilization of protein-protein interactions in drug discovery. Andrei SA, Sijbesma E, Hann M, Davis J, O'Mahony G, Perry MWD, Karawajczyk A, Eickhoff J, Brunsveld L, Doveston RG, Milroy LG, Ottmann C. Expert Opin Drug Discov 12 925-940 (2017)
  9. ERRγ: a Junior Orphan with a Senior Role in Metabolism. Misra J, Kim DK, Choi HS. Trends Endocrinol Metab 28 261-272 (2017)
  10. A structural view of nuclear hormone receptor: endocrine disruptor interactions. le Maire A, Bourguet W, Balaguer P. Cell Mol Life Sci 67 1219-1237 (2010)
  11. Advances in our structural understanding of orphan nuclear receptors. Gallastegui N, Mackinnon JA, Fletterick RJ, Estébanez-Perpiñá E. Trends Biochem Sci 40 25-35 (2015)
  12. Esrrb, an estrogen-related receptor involved in early development, pluripotency, and reprogramming. Festuccia N, Owens N, Navarro P. FEBS Lett 592 852-877 (2018)
  13. Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Riggins RB, Mazzotta MM, Maniya OZ, Clarke R. Endocr Relat Cancer 17 R213-31 (2010)
  14. Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renaissance? Divekar SD, Tiek DM, Fernandez A, Riggins RB. Nucl Recept Signal 14 e002 (2016)
  15. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. Roshan-Moniri M, Hsing M, Butler MS, Cherkasov A, Rennie PS. Cancer Treat Rev 40 1137-1152 (2014)
  16. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer. Fletterick RJ. BJU Int 96 Suppl 2 2-9 (2005)
  17. Transcriptional Regulation of ROS Homeostasis by the ERR Subfamily of Nuclear Receptors. Scholtes C, Giguère V. Antioxidants (Basel) 10 437 (2021)
  18. The emerging role of estrogen related receptorα in complications of non-small cell lung cancers. Mukherjee TK, Malik P, Hoidal JR. Oncol Lett 21 258 (2021)
  19. Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. Aesoy R, Clyne CD, Chand AL. Front Endocrinol (Lausanne) 6 115 (2015)
  20. Molecular dynamics of estrogen-related receptors and their regulatory proteins: roles in transcriptional control for endocrine and metabolic signaling. Tanida T. Anat Sci Int 97 15-29 (2022)
  21. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, Jetten AM, Edwards DP, Grimm SL, Hartig S, Lange CA, Richer JK, Sartorius CA, Tetel M, Billon C, Elgendy B, Hegazy L, Griffett K, Peinetti N, Burnstein KL, Hughes TS, Sitaula S, Stayrook KR, Culver A, Murray MH, Finck BN, Cidlowski JA. Pharmacol Rev 75 1233-1318 (2023)

Articles citing this publication (44)

  1. Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity. Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, Shimohigashi Y. Toxicol Lett 167 95-105 (2006)
  2. Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, Shimohigashi Y. Environ Health Perspect 116 32-38 (2008)
  3. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, Gabrielson KL, Takimoto E, Kass DA. Circ Res 105 12-15 (2009)
  4. Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP. Ortlund EA, Lee Y, Solomon IH, Hager JM, Safi R, Choi Y, Guan Z, Tripathy A, Raetz CR, McDonnell DP, Moore DD, Redinbo MR. Nat Struct Mol Biol 12 357-363 (2005)
  5. Protein evolution by molecular tinkering: diversification of the nuclear receptor superfamily from a ligand-dependent ancestor. Bridgham JT, Eick GN, Larroux C, Deshpande K, Harms MJ, Gauthier ME, Ortlund EA, Degnan BM, Thornton JW. PLoS Biol 8 e1000497 (2010)
  6. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R. Cancer Res 68 8908-8917 (2008)
  7. Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Shan L, Vincent J, Brunzelle JS, Dussault I, Lin M, Ianculescu I, Sherman MA, Forman BM, Fernandez EJ. Mol Cell 16 907-917 (2004)
  8. Ncoa3 functions as an essential Esrrb coactivator to sustain embryonic stem cell self-renewal and reprogramming. Percharde M, Lavial F, Ng JH, Kumar V, Tomaz RA, Martin N, Yeo JC, Gil J, Prabhakar S, Ng HH, Parker MG, Azuara V. Genes Dev 26 2286-2298 (2012)
  9. Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds. Delfosse V, Dendele B, Huet T, Grimaldi M, Boulahtouf A, Gerbal-Chaloin S, Beucher B, Roecklin D, Muller C, Rahmani R, Cavaillès V, Daujat-Chavanieu M, Vivat V, Pascussi JM, Balaguer P, Bourguet W. Nat Commun 6 8089 (2015)
  10. Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. Chao EY, Collins JL, Gaillard S, Miller AB, Wang L, Orband-Miller LA, Nolte RT, McDonnell DP, Willson TM, Zuercher WJ. Bioorg Med Chem Lett 16 821-824 (2006)
  11. ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner. Matsushima A, Teramoto T, Okada H, Liu X, Tokunaga T, Kakuta Y, Shimohigashi Y. Biochem Biophys Res Commun 373 408-413 (2008)
  12. A simple and fuzzy method to align and compare druggable ligand-binding sites. Schalon C, Surgand JS, Kellenberger E, Rognan D. Proteins 71 1755-1778 (2008)
  13. ERRgamma regulates cardiac, gastric, and renal potassium homeostasis. Alaynick WA, Way JM, Wilson SA, Benson WG, Pei L, Downes M, Yu R, Jonker JW, Holt JA, Rajpal DK, Li H, Stuart J, McPherson R, Remlinger KS, Chang CY, McDonnell DP, Evans RM, Billin AN. Mol Endocrinol 24 299-309 (2010)
  14. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. Molnár F, Matilainen M, Carlberg C. J Biol Chem 280 26543-26556 (2005)
  15. The orphan nuclear receptor small heterodimer partner mediates male infertility induced by diethylstilbestrol in mice. Volle DH, Decourteix M, Garo E, McNeilly J, Fenichel P, Auwerx J, McNeilly AS, Schoonjans K, Benahmed M. J Clin Invest 119 3752-3764 (2009)
  16. Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. Rastinejad F, Ollendorff V, Polikarpov I. Trends Biochem Sci 40 16-24 (2015)
  17. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration. Wang X, Zhao L, Zhang Y, Ma W, Gonzalez SR, Fan J, Kretschmer F, Badea TC, Qian HH, Wong WT. J Neurosci 37 3294-3310 (2017)
  18. Active nuclear receptors exhibit highly correlated AF-2 domain motions. Teotico DG, Frazier ML, Ding F, Dokholyan NV, Temple BR, Redinbo MR. PLoS Comput Biol 4 e1000111 (2008)
  19. Structural determination of estrogen-related receptor gamma in the presence of phenol derivative compounds. Abad MC, Askari H, O'Neill J, Klinger AL, Milligan C, Lewandowski F, Springer B, Spurlino J, Rentzeperis D. J Steroid Biochem Mol Biol 108 44-54 (2008)
  20. Receptor binding characteristics of the endocrine disruptor bisphenol A for the human nuclear estrogen-related receptor gamma. Chief and corroborative hydrogen bonds of the bisphenol A phenol-hydroxyl group with Arg316 and Glu275 residues. Liu X, Matsushima A, Okada H, Tokunaga T, Isozaki K, Shimohigashi Y. FEBS J 274 6340-6351 (2007)
  21. Distinct mechanisms of endocrine disruption of DDT-related pesticides toward estrogen receptor α and estrogen-related receptor γ. Zhuang S, Zhang J, Wen Y, Zhang C, Liu W. Environ Toxicol Chem 31 2597-2605 (2012)
  22. A frequent regulatory variant of the estrogen-related receptor alpha gene associated with BMD in French-Canadian premenopausal women. Laflamme N, Giroux S, Loredo-Osti JC, Elfassihi L, Dodin S, Blanchet C, Morgan K, Giguère V, Rousseau F. J Bone Miner Res 20 938-944 (2005)
  23. Estrogen receptor-related receptor-alpha (ERR-alpha) is dysregulated in inflammatory arthritis. Bonnelye E, Laurin N, Jurdic P, Hart DA, Aubin JE. Rheumatology (Oxford) 47 1785-1791 (2008)
  24. Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780). Fitts JM, Klein RM, Powers CA. J Pharmacol Exp Ther 338 246-254 (2011)
  25. A molecular switch regulating transcriptional repression and activation of PPARγ. Shang J, Mosure SA, Zheng J, Brust R, Bass J, Nichols A, Solt LA, Griffin PR, Kojetin DJ. Nat Commun 11 956 (2020)
  26. Genes targeted by the Hedgehog-signaling pathway can be regulated by Estrogen related receptor β. Lu Y, Li J, Cheng J, Lubahn DB. BMC Mol Biol 16 19 (2015)
  27. Development of a coactivator displacement assay for the orphan receptor estrogen-related receptor-gamma using time-resolved fluorescence resonance energy transfer. Gowda K, Marks BD, Zielinski TK, Ozers MS. Anal Biochem 357 105-115 (2006)
  28. Distinction of the binding modes for human nuclear receptor ERRgamma between bisphenol A and 4-hydroxytamoxifen. Liu X, Matsushima A, Okada H, Shimohigashi Y. J Biochem 148 247-254 (2010)
  29. The history of Distilbène® (Diethylstilbestrol) told to grandchildren--the transgenerational effect. Fénichel P, Brucker-Davis F, Chevalier N. Ann Endocrinol (Paris) 76 253-259 (2015)
  30. Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP. Kalach JJ, Joly-Pharaboz MO, Chantepie J, Nicolas B, Descotes F, Mauduit C, Benahmed M, André J. J Steroid Biochem Mol Biol 96 119-129 (2005)
  31. Structural insights into Estrogen Related Receptor-β modulation: 4-methylenesterols from Theonella swinhoei sponge as the first example of marine natural antagonists. Di Micco S, Renga B, Carino A, D'Auria MV, Zampella A, Riccio R, Fiorucci S, Bifulco G. Steroids 80 51-63 (2014)
  32. Association of estrogen receptor β and estrogen-related receptor α gene polymorphisms with bone mineral density in postmenopausal women. Shoukry A, Shalaby SM, Etewa RL, Ahmed HS, Abdelrahman HM. Mol Cell Biochem 405 23-31 (2015)
  33. Importance of the Sequence-Directed DNA Shape for Specific Binding Site Recognition by the Estrogen-Related Receptor. Mohideen-Abdul K, Tazibt K, Bourguet M, Hazemann I, Lebars I, Takacs M, Cianférani S, Klaholz BP, Moras D, Billas IML. Front Endocrinol (Lausanne) 8 140 (2017)
  34. Local motifs involved in the canonical structure of the ligand-binding domain in the nuclear receptor superfamily. Tsuji M. J Struct Biol 185 355-365 (2014)
  35. Generation and characterization of human steroidogenic factor 1 LBD crystals with and without bound cofactor peptide. Madauss K, Juzumiene D, Waitt G, Williams J, Williams S. Endocr Res 30 775-785 (2004)
  36. Delineation of the molecular determinants of the unique allosteric binding site of the orphan nuclear receptor RORγt. Leijten-van de Gevel IA, Brunsveld L. J Biol Chem 295 9183-9191 (2020)
  37. Insights into the activation mechanism of human estrogen-related receptor γ by environmental endocrine disruptors. Thouennon E, Delfosse V, Bailly R, Blanc P, Boulahtouf A, Grimaldi M, Barducci A, Bourguet W, Balaguer P. Cell Mol Life Sci 76 4769-4781 (2019)
  38. Computer-aided design and synthesis of tetra-aryl-substituted alkenes and their bioevaluation as a selective modulator of estrogen-related receptor γ. Koh M, Park SB. Mol Divers 15 69-81 (2011)
  39. An Inverse Agonist GSK5182 Increases Protein Stability of the Orphan Nuclear Receptor ERRγ via Inhibition of Ubiquitination. Na SY, Kim KS, Jung YS, Kim DK, Kim J, Cho SJ, Lee IK, Chung J, Kim JS, Choi HS. Int J Mol Sci 24 96 (2022)
  40. Subcellular dynamics of estrogen-related receptors involved in transrepression through interactions with scaffold attachment factor B1. Tanida T, Matsuda KI, Uemura T, Yamaguchi T, Hashimoto T, Kawata M, Tanaka M. Histochem Cell Biol 156 239-251 (2021)
  41. [Endocrine disruptors and fertility: NR0B2, a new therapeutic target?]. Decourteix M, Volle DH. Med Sci (Paris) 26 359-361 (2010)
  42. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. Hampton CS, Sitaula S, Billon C, Haynes K, Avdagic A, Wanninayake U, Adeyemi CM, Chatterjee A, Griffett K, Banerjee S, Burris SL, Schoepke E, Boehm T, Bess A, de Vera IMS, Burris TP, Walker JK. Eur J Med Chem 258 115582 (2023)
  43. Enhancement of initial equivalency for protein structure alignment based on encoded local structures. Hung K, Wang JC, Chen CW, Chuang CL, Tsai KN, Chen CM. IEEE Trans Inf Technol Biomed 16 1185-1192 (2012)
  44. Total synthesis of eryvarin H and its derivatives and their biological activity as ERRγ inverse agonist. Koo JY, Oh S, Cho SR, Koh M, Oh WK, Choi HS, Park SB. Org Biomol Chem 11 5782-5786 (2013)


Quick links